A financial firm based in Asia has created a healthcare-focused US$100 million evergreen fund. The firm seeks to participate in Series A to C rounds and is open to leading or following. Typical investments range from US$0.5 to 2 million, while larger investments can be considered on a case-by-case basis. The firm expects to make 4-5 new deals in the coming 12 months. The firm is currently seeking opportunities from the US and Canada.
The firm considers opportunities broadly across the healthcare field, including biomedicine, medical devices, diagnostics. The firm currently has an increased interest in healthcare IT. When it comes to overseas deals, the firm prefers products that have achieved prototype and clinical proof-of-concept. The firm is opportunistic in terms of disease areas.
The firm is looking for competent and experienced management teams. The firm does not require board representation after investment. As a financially-driven investor, the firm does not typically request regional rights, but it can provide assistance with finding local partners.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment